|Last Price$8.68||Day Change (%)0.12%|
|Open Price$8.70||Day Change ($)0.01|
|Day Range8.60–8.73||52-Week Range6.72–10.18|
As of Wed 06/19/2013 12:12 PM EDT | USD
Looking for bargains where others are bailing out.
Janus Capital's Gibson Smith expects more of a gradual shift out of fixed-income securities
Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis
Fairholme takes a big stake in Fannie and Freddie preferreds, a manager of a Bronze-rated Oppenheimer fund departs, Templeton Frontier Markets closes to new investors, a slew of manager changes at Bridgeway, and some high-profile Janus fund managers resurface at a hedge fund.
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Also, Vanguard rolls out an emerging-markets bond fund, major portfolio manager departures at T. Rowe Price and FPA, Neuberger Berman to launch a China fund, and Invesco to rework its quant funds.
Enrique Chang becomes a co-CIO at Janus , replacing Jonathan Coleman, who will focus on managing Janus Fund. American Century's new CIO search starts immediately.
Janus Capital Group Inc., owner of the Janus , Intech and Perkins funds, said first-quarter earnings rose 24% as stock market gains helped boost assets.
Richard Weil, chief executive officer at Janus Capital Group, had his compensation reduced 19% to $4.98 million in 2012 as investors withdrew $12.1 billion from the firm.